MetLife (MET) Form 4: Director Diana McKenzie Acquires 158 Shares

MetLife director Diana McKenzie reported a small insider acquisition under Form 4.

Rhea-AI Filing Summary

MetLife director Diana McKenzie reported a small insider acquisition under Form 4. On 09/09/2025 she received 158 shares of MetLife common stock at an imputed price of $79.29 through reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors. After the transaction her beneficial ownership is reported as 22,223 shares held directly. The Form 4 was filed as a single reporting person filing and signed on behalf of the reporting person by an attorney-in-fact on 09/11/2025.

Positive

• Increased direct ownership to 22,223 shares via dividend reinvestment
• Transaction disclosed timely on Form 4 and filed by one reporting person

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine dividend reinvestment added 158 shares, marginally increasing a director's direct stake to 22,223 shares.

The reported 158-share acquisition is described as an imputed reinvestment of dividends from the company's deferred compensation plan for non-management directors. The transaction price is listed as $79.29, which is an imputed price used for recordkeeping. This is a routine, non-discretionary transaction that does not indicate new open-market buying by the director and is unlikely to be material to MetLife's valuation given the small size relative to typical public-company market capitalization.

Corporate Governance Expert

TL;DR: Disclosure aligns with Section 16 reporting rules and shows routine plan-driven share accumulation by a director.

The filing identifies the relationship as Director and the ownership form as direct, with the acquisition resulting from the director's deferral plan. The Form 4 correctly discloses the transaction date and the mechanics: dividend reinvestment of deferred shares. The presence of an attorney-in-fact signature is consistent with administrative filing practice. There are no indications of atypical or compensatory equity grants in this report.

Insider Trade Summary

Grant/Award: 158 shares

Grant/Award 1 txn

Insider MCKENZIE DIANA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	158	$79.29	$13K

Holdings After Transaction: Common Stock — 22,223 shares (Direct)

Footnotes (1)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did MetLife director Diana McKenzie report on Form 4 (MET)?

The Form 4 reports an imputed reinvestment of dividends resulting in the acquisition of 158 shares on 09/09/2025.

How many MetLife shares does Diana McKenzie own after this transaction?

Following the reported transaction she beneficially owns 22,223 shares held directly.

What price is listed for the shares acquired on the Form 4?

The transaction shows an imputed price of $79.29 per share.

Why were the shares acquired according to the filing?

The acquisition is explained as imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors.

When was the Form 4 signed and filed?

The signature by an attorney-in-fact is dated 09/11/2025; the reported transaction date is 09/09/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/11/2025 - 04:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCKENZIE DIANA

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NY 10166

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/09/2025		A(1)		158	A	$79.29	22,223	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Deferred Compensation Plan for Non-Management Directors. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the director has deferred.

Remarks:

	/s/ Taylor McInerney Jansen, Attorney-in-fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.